A third of clinical trials publishing interim findings fail to report final results, review findsBMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k317 (Published 23 January 2018) Cite this as: BMJ 2018;360:k317
All rapid responses
Clinical research trials are playing a vital role in quality and safety of new drugs. Almost all clinical trials are sponsored by pharma companies, while government and its agencies will only sponsor a few clinical trials especially in areas of main epidemics like HIV, etc., and in the arena of traditional medicines. Most studies reveal that pharma companies' mode of clinical trials is either in-house or outsourced. The main strength of these kinds of studies will boost the R & D sector and the development of new drug molecules. Industry must use proper and creative technologies to reducing the cost and focus on risk management like minimize deformities, mitigate adverse reaction and untoward effects.
Other issues include drawbacks in clinical research like the strategic shift observed in finding emerging markets and meeting the unmet medical needs there. The weakness of any clinical trial is improper study design, sample size, and publication bias. Threats are associated with time constraints, improper patient follow up, and legal issues. The other important and significant challenge is the execution of clinical trials, and in general most pharma companies don’t do a good job of engaging their clinical trials in a proper way. Pharma giants must focus on people instead of performance number of their trials. These companies take care of their research team and people involved in the trial with the utmost dignity, and respect will deliver a better outcome.
In conclusion, all those involved in any kind of clinical trial must know that these researchers are patient-centric. But the pharma segment of the Healthcare industry is not much appreciated. Clinical trials are fairly well developed and grossly underserved at the same time. So it is the right time to motivate with trust and let the sponsoring agencies do justice to their clinical trials and treat people as human beings, not as guinea pigs.
Competing interests: No competing interests